132 related articles for article (PubMed ID: 34405207)
1. Razumab -- the role of biosimilars for the treatment of retinal diseases.
Ferro Desideri L; Cutolo CA; Traverso CE; Nicolò M
Drugs Today (Barc); 2021 Aug; 57(8):499-505. PubMed ID: 34405207
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?
Chatzimichail E; Pfau K; Gatzioufas Z; Panos GD
Drug Des Devel Ther; 2024; 18():365-374. PubMed ID: 38347957
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars for Retinal Diseases: An Update.
Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
Am J Ophthalmol; 2021 Apr; 224():36-42. PubMed ID: 33309691
[TBL] [Abstract][Full Text] [Related]
4. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review.
Bressler NM; Kaiser PK; Do DV; Nguyen QD; Park KH; Woo SJ; Sagong M; Bradvica M; Kim MY; Kim S; Sadda SR
Surv Ophthalmol; 2024; 69(4):521-538. PubMed ID: 38521423
[TBL] [Abstract][Full Text] [Related]
6. Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence.
Kelkar AS; Kelkar J; Bolisetty M; Kelkar SB
Indian J Ophthalmol; 2021 Jun; 69(6):1469-1474. PubMed ID: 34011722
[TBL] [Abstract][Full Text] [Related]
7. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.
Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
Expert Opin Biol Ther; 2023; 23(8):689-692. PubMed ID: 37470687
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
9. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
Waisbourd M; Goldstein M; Loewenstein A
Isr Med Assoc J; 2011 Mar; 13(3):141-6. PubMed ID: 21608333
[TBL] [Abstract][Full Text] [Related]
10. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.
Chakraborty D; Stewart MW; Sheth JU; Sinha TK; Boral S; Das A; Mondal S; Mukherjee A
Ophthalmol Ther; 2021 Jun; 10(2):337-348. PubMed ID: 33864599
[TBL] [Abstract][Full Text] [Related]
11. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
12. Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.
Sharma S; Sharma T; Prasad S; Gopalakrishnan M; Chaturvedi A
Ophthalmol Ther; 2021 Sep; 10(3):431-443. PubMed ID: 34155608
[TBL] [Abstract][Full Text] [Related]
13. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
14. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
15. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
16. [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
Katz G; Zehavi C; Treister G
Harefuah; 2015 Apr; 154(4):270-3, 278. PubMed ID: 26065226
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab for myopic choroidal neovascularization.
Ng DSC; Fung NSK; Yip FLT; Lai TYY
Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
[TBL] [Abstract][Full Text] [Related]
18. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY.
Kaiser PK; Schmitz-Valckenberg MS; Holz FG
Retina; 2022 Dec; 42(12):2243-2250. PubMed ID: 36394884
[TBL] [Abstract][Full Text] [Related]
19. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
20. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
